Provided by Tiger Fintech (Singapore) Pte. Ltd.

Outlook Therapeutics, Inc.

1.57
+0.09006.08%
Post-market: 1.570.00000.00%18:42 EDT
Volume:351.28K
Turnover:546.53K
Market Cap:50.27M
PE:-0.39
High:1.57
Open:1.50
Low:1.50
Close:1.48
Loading ...

Company Profile

Company Name:
Outlook Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
23
Office Location:
111 S. Wood Avenue,Unit #100,Iselin,New Jersey,United States
Zip Code:
08830
Fax:
- -
Introduction:
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Directors

Name
Position
C. Russell Trenary III
President, Chief Executive Officer and Director
Ralph H. Thurman
Executive Chairman of the Board, Director
Lawrence A. Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
Andong Huang
Director
Faisal G. Sukhtian
Director
Gerd Auffarth
Director
Julia A. Haller
Director
Julian Gangolli
Director
Kurt J. Hilzinger
Director
Yezan Haddadin
Director

Shareholders

Name
Position
C. Russell Trenary III
President, Chief Executive Officer and Director
Lawrence A. Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director
Jeff Evanson
Chief Commercial Officer